EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R 1 , R 2 , R 3a , R 3b , R 4a , R 4b and R 5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
1 .- 19 . (canceled)
20 . A compound having the structure:
or a pharmaceutically acceptable salt thereof.
21 . A compound having the structure:
22 . A method for treating an eIF4A dependent condition in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof.
23 . The method according to claim 22 wherein the eIF4A dependent condition is a disease of uncontrolled cell growth, proliferation and/or survival, or is a disease of inappropriate cellular inflammatory responses.
24 . The method according to claim 22 wherein the eIF4A dependent condition is a disease of uncontrolled cell growth, proliferation and/or survival.
25 . The method according to claim 24 wherein the eIF4A dependent condition is cancer.
26 . The method of claim 25 wherein the eIF4A dependent condition is a solid tumor, colorectal cancer, bladder cancer, gastric cancer, thyroid cancer, esophageal cancer, head and neck cancer, brain cancer, malignant glioma, fibrotic diseases, glioblastoma, hepatocellular cancers, thyroid cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, melanoma, multiple melanoma, myeloma, pancreatic cancer, pancreatic carcinoma, renal cell carcinoma, renal cancer, cervical cancer, urothelial cancer, prostate cancer, castration-resistant prostate cancer, ovarian cancer, breast cancer, triple-negative breast cancer, leukemia, acute myeloid leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, multiple myeloma, myelodysplastic syndrome, Alzheimer's, Parkinson's, Fragile X Syndrome and autism disorders.
27 . The method of claim 26 wherein the eIF4A dependent condition is hepatocellular cancers, breast cancer, small cell lung cancer and non-small cell lung cancer.
28 . The method of claim 26 wherein the eIF4A dependent condition is diffuse large B-cell lymphoma, Burkitt's lymphoma, acute myeloid leukemia, triple-negative breast cancer and colorectal cancer.